Guide contents
Open in calculatorCompound briefing
GLOW is a pre-mixed triple peptide blend combining BPC-157 (10mg), GHK-Cu (50mg) and TB500 (10mg) in a single 70mg vial. The blend is studied in research contexts for its complementary effects on collagen synthesis, dermal remodelling, angiogenesis, hair-follicle support and systemic soft-tissue recovery — bringing together a cytoprotective driver (BPC-157), a copper-binding transcriptomic modulator (GHK-Cu) and a systemic cell-migration regulator (TB500) in one reconstitution.
The research question
GLOW brings together copper-mediated remodelling, cytoprotection and actin-related cell migration. Research records should identify each constituent separately so that concentration, colour and exposure are not confused by total blend mass.
Mechanism & research themes
BPC-157 upregulates the NO system, VEGF/EGF signalling and the FAK-paxillin pathway to accelerate fibroblast migration and local tissue repair. GHK-Cu acts as a tissue-damage signal that modulates over 4,000 genes, driving collagen I/III synthesis, antioxidant SOD activity and stem-cell chemoattraction. TB500 sequesters G-actin monomers to regulate actin polymerisation, supporting angiogenesis, systemic progenitor cell recruitment and dermal remodelling.
Combined dermal collagen, elastin and angiogenic support
Synergistic hair-follicle anagen-phase extension and density signals
Accelerated wound closure and re-epithelialisation
Soft-tissue, tendon and ligament recovery from the BPC-157 / TB500 pairing
Transcriptome-level skin rejuvenation via GHK-Cu
Single-vial convenience replacing three separate reconstitutions
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
No robust controlled evidence validates the blend as a single intervention. Its rationale is assembled from separate compounds with different evidence quality and safety considerations.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 250–500mcg of the blend subcutaneously once daily, or split morning/evening, with administration adjacent to target areas (e.g. dermal or scalp regions) for localised effect. Cycles typically run 4–8 weeks on / 2–4 weeks off.
Reported persistence
BPC-157 approximately 4 hours; GHK-Cu plasma approximately 0.5–1 hour with prolonged tissue activity; TB500 approximately 30–80 minutes with multi-day depot effect.
Calculator starting point
0.3 mg per reference dose
5 doses per week · 8-week cycle
3 mL default reconstitution volume
Skin/recovery blend; 5×/week over 6–10 week cycles.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate GLOWLaboratory handling
Reconstitution reference
Reconstitute the 70mg vial with 2–3mL bacteriostatic water, injected slowly down the side of the vial. Swirl gently — do not shake. Solution will take on a faint blue-green tint from the copper complex; this is expected.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Theoretical VEGF / angiogenesis caution flagged across the BPC-157 and TB500 literature — precautionary for subjects with active neoplastic tissue.
GHK-Cu adds a theoretical copper-accumulation concern at chronic high systemic doses — avoid in Wilson's disease or copper-metabolism disorders.
Mild injection-site redness, warmth or transient 'head rush' (TB500) may occur; tolerability is otherwise considered favourable in research.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading